|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to determine the diagnostic significance of monoclonal PAX8 antibody in distinguishing ITTCs from follicular cell-derived thyroid carcinomas.
|
30210064 |
2018 |
|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A subset of thyroid carcinomas expresses an oncogenic paired box 8 (PAX8) and peroxisome proliferator activated receptor γ (PPARγ) fusion protein (PPFP).
|
29373711 |
2018 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Follicular thyroid cancers harbor translocations and fusions of certain genes (PAX 8 and PPAR-gamma).
|
20578236 |
2010 |
|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we demonstrated an inverse correlation between expression of PAX8 and STK17B in a set of cell lines derived from human thyroid carcinomas.
|
24086368 |
2013 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TSH receptor mRNA reverse transcription-polymerase chain reaction, the Veracyte and Asuragen commercial methods, and the noncommercial use of BRAF, RAS, RET/PTC, and PAX8/PPARγ testing have promising roles in the diagnosis and treatment of patients with nodular thyroid disease and thyroid cancer.
|
22984796 |
2013 |
|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To correlate the differentiation phenotype of two human thyroid cancer cell lines with their expression of various molecular markers, we analyzed the mRNA levels of four thyroid-specific genes, including thyrotropin receptor (TSHR), thyroglobulin (Tg), thyroid transcription factor-1 (TTF-1), and paired-box containing transcription factor-8 (PAX-8) genes.
|
10810302 |
2000 |
|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PAX8 is a thyroid-specific transcription factor whose expression is dysregulated in thyroid cancer.
|
27249794 |
2016 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PPARgamma may play a role in thyroid carcinogenesis since PAX8-PPARgamma1 chromosomal translocations are commonly found in follicular thyroid cancers.
|
15785241 |
2005 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The human TTF-1 and Pax-8 gene were transducted into the human thyroid carcinoma (K1 and F133) cells by the recombinant adenovirus, AdTTF-1 and AdPax-8.
|
22498723 |
2012 |
|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Induction of TTF-1 or PAX-8 expression on proliferation and tumorigenicity in thyroid carcinomas.
|
27573549 |
2016 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A PAX8-PPARγ fusion protein (PPFP) is oncogenic in a subset of thyroid cancers, suggesting that inhibition of endogenous PPARγ function by the fusion protein could contribute to thyroid oncogenesis.
|
29420754 |
2018 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARγ chromosomal rearrangements.
|
21878896 |
2011 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPARgamma rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs).
|
19147628 |
2009 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As such, this article addresses the following aspects of intragenic mutations in thyroid cancer: thyroid stimulating hormone receptor and guanine-nucleotide-binding proteins of the stimulatory family mutations in hyperfunctioning tumors; mutations in RAS and other genes and aneuploidy; PAX8-PPARgamma rearrangements; BRAF mutations; mutations in oxidative phosphorylation and Krebs cycle genes in Hürthle cell tumors; mutations in succinate dehydrogenase genes in medullary carcinoma and C-cell hyperplasia; and mutations in TP53 and other genes in poorly differentiated and anaplastic carcinomas.
|
18502330 |
2008 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The experiments demonstrate an oncogenic role for PPARgamma and suggest that PAX8-PPARgamma1 may be useful in the diagnosis and treatment of thyroid carcinoma.
|
10958784 |
2000 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cotransduction of AdTTF-1 and AdTGTK permitted 90% cytotoxicity for BHP15-3 and >95% cytotoxicity for FRT, as well as for BHP7-13 and BHP18-21v thyroid cancer cell lines [both/TTF1(-)/TTF-2(-)/Pax-8(+)/TG(-)].
|
11325833 |
2001 |
|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Because of the more favorable prognosis for PTC in children compared to young patients, we hypothesized that Pax-8 expression might be different in pediatric thyroid cancers.
|
15650356 |
2004 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pax-8-PPAR-γ fusion protein in thyroid carcinoma.
|
25069464 |
2014 |
|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We therefore examined the effects of overexpression of TTF-1 and PAX-8 on Tg gene promoter activity in the human thyroid carcinoma cell lines, ARO (anaplastic) and WRO (follicular).
|
9854590 |
1998 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also highlight high-confidence gene fusions supported by both genomic and transcriptomic evidence, including a previously undescribed paired box 8 (PAX8)-nuclear factor, erythroid 2 like 2 (NFE2L2) fusion in thyroid carcinoma.
|
27856756 |
2016 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present findings provide evidence that LDR-induced PAX8 acts as an important regulator for suppression of thyroid carcinogenesis through novel STAT3/miR-330-5p pathway in thyroid cancers.
|
30760304 |
2019 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this review, we will summarize the histologic features of known recurrent genomic rearrangements in carcinomas, especially focusing on TMPRSS2-ERG fusion in prostate cancer, EML4-ALK in lung cancer, ETV6-NTRK3 in secretory breast cancer, RET/PTC and PAX8/PPARγ1 rearrangements in thyroid cancer.
|
23060067 |
2012 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diagnostic and prognostic implications of the PAX8-PPARγ translocation in thyroid carcinomas-a TMA-based study of 226 cases.
|
23738683 |
2013 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pax-8-expressing thyroid carcinoma cells were selectively killed by radioiodine.
|
21833035 |
2012 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is the first report of napsin A-positive and PAX8-negative thyroid carcinoma and highlights the pitfalls of clinicopathological diagnosis.
|
31653481 |
2019 |